M Holdings Securities Inc. lowered its position in Zoetis Inc. (NYSE:ZTS – Get Rating) by 7.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 2,867 shares of the company’s stock after selling 225 shares during the period. M Holdings Securities Inc.’s holdings in Zoetis were worth $425,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Zoetis by 0.9% during the third quarter. Vanguard Group Inc. now owns 36,550,676 shares of the company’s stock worth $5,420,101,000 after buying an additional 315,032 shares during the last quarter. State Street Corp raised its holdings in shares of Zoetis by 0.4% during the third quarter. State Street Corp now owns 19,803,022 shares of the company’s stock valued at $2,936,590,000 after purchasing an additional 83,221 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Zoetis by 2.2% during the third quarter. Alliancebernstein L.P. now owns 19,102,111 shares of the company’s stock valued at $2,832,652,000 after purchasing an additional 408,379 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Zoetis by 4.0% during the third quarter. Price T Rowe Associates Inc. MD now owns 10,406,006 shares of the company’s stock valued at $1,548,588,000 after purchasing an additional 395,882 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Zoetis by 2.1% during the second quarter. Massachusetts Financial Services Co. MA now owns 5,330,676 shares of the company’s stock valued at $916,289,000 after purchasing an additional 109,811 shares during the period. 90.23% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, Barclays upped their price objective on shares of Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Tuesday, February 21st. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $223.83.
Zoetis Trading Down 0.6 %
Zoetis (NYSE:ZTS – Get Rating) last issued its quarterly earnings data on Tuesday, February 14th. The company reported $1.15 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.15. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the prior year, the firm posted $1.00 EPS. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. As a group, research analysts predict that Zoetis Inc. will post 5.39 earnings per share for the current fiscal year.
Zoetis Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Stockholders of record on Friday, April 21st will be given a dividend of $0.375 per share. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Thursday, April 20th. Zoetis’s dividend payout ratio is currently 33.33%.
Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Get Rating).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.